Shivakumar Ajay Kumar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Shivakumar Ajay Kumar has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Anuradha Shenoy
ESIC MC & PGIMSR
1 shared publication - Deepthi Ramamurthy
ESIC Model Hospital & PGIMSR
1 shared publication - Ravi Chandra C. V.
Department of Pharmacology, ESIC Medical College PGIMSR and Model Hospital, Rajajinagar, Bangalore, Karnataka, India
1 shared publication - Suthanthira Kannan
Department of Community Medicine, ESIC Medical College & Hospital, Chennai, India
1 shared publication
Latest Publications
- Open Access
- 1 July 2024
- Published by Apex Publishing in Journal of Medical Education Development
- Vol. 17 (54) , 131-138
Effectiveness of delivering disability competencies to undergraduate medical students in a foundation course in a Government Medical College: A quasi-experimental study
Background & Objective: Globally, 16% of the world’s population, or 1 in 6 of us, experience significant disability. Persons with Disabilities (PWDs) are likely to encounter insufficient healthcare provider skills to address their specific needs, to encounter denial of care, and to experience mistreatment from healthcare providers. In the diverse field of ...
- 1 July 2024
- Published by Apex Publishing in Journal of Medical Education Development
- Vol. 17 (54) , 131-138
Open AccessEffectiveness of delivering disability competencies to undergraduate medical students in a foundation course in a Government Medical College: A quasi-experimental study
Background & Objective: Globally, 16% of the world’s population, or 1 in 6 of us, experience significant disability. Persons with Disabilities (PWDs) are likely to encounter insufficient healthcare provider skills to address their specific needs, to encounter denial of care, and to experience mistreatment from healthcare providers. In the diverse field of ...
- Open Access
- 22 April 2022
- Published by Medip Academy in International Journal of Basic & Clinical Pharmacology
- Vol. 11 (3) , 275-278
Investigational synthetic neuroactive steroid zuranolone in treatment of major depressive disorder with peripartum onset
Major depressive disorder with peripartum onset or peripartum depression is a common condition experienced by a large proportion of women and to some extent even in men. The current treatment strategies involve the use of conventional pharmacotherapeutic classes of drugs like selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs) and psychotherapy methods in the management of this condition. In this article, we try to review and evaluate the pathophysiology of the condition along with the safety and efficacy of the novel investigational therapeutic drug zuranolone, which is a synthetic neuroactive steroid (NAS) that has shown promise in clinical trials for the management of conditions like major depressive disorder, peripartum depression and bipolar disorder. The synthetic NAS zuranolone is an orally bioavailable positive allosteric modulator of the gamma amino butyric acid (GABAA) receptor, which can regulate the action of the GABAergic pathway implicated in many depressive episodes and also affect the normal functioning of the hypothalmo pituitary-adrenal (HPA) axis which is the core pathophysiological cause behind major depressive disorder with peripartum onset.
- 22 April 2022
- Published by Medip Academy in International Journal of Basic & Clinical Pharmacology
- Vol. 11 (3) , 275-278
Open AccessInvestigational synthetic neuroactive steroid zuranolone in treatment of major depressive disorder with peripartum onset
Major depressive disorder with peripartum onset or peripartum depression is a common condition experienced by a large proportion of women and to some extent even in men. The current treatment strategies involve the use of conventional pharmacotherapeutic classes of drugs like selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs) and psychotherapy methods in the management of this condition. In this article, we try to review and evaluate the pathophysiology of the condition along with the safety and efficacy of the novel investigational therapeutic drug zuranolone, which is a synthetic neuroactive steroid (NAS) that has shown promise in clinical trials for the management of conditions like major depressive disorder, peripartum depression and bipolar disorder. The synthetic NAS zuranolone is an orally bioavailable positive allosteric modulator of the gamma amino butyric acid (GABAA) receptor, which can regulate the action of the GABAergic pathway implicated in many depressive episodes and also affect the normal functioning of the hypothalmo pituitary-adrenal (HPA) axis which is the core pathophysiological cause behind major depressive disorder with peripartum onset.